203 related articles for article (PubMed ID: 19042143)
1. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
2. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
3. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism.
Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195
[TBL] [Abstract][Full Text] [Related]
6. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Arenas Bermejo C; Pérez Alenza D; García San José P; Llauet L; Pérez-López L; Melián C; C Feldman E
J Vet Intern Med; 2020 Jul; 34(4):1413-1422. PubMed ID: 32533623
[TBL] [Abstract][Full Text] [Related]
7. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
Reid LE; Behrend EN; Martin LG; Kemppainen RJ; Ward CR; Lurye JC; Donovan TC; Lee HP
J Vet Intern Med; 2014; 28(2):443-50. PubMed ID: 24400747
[TBL] [Abstract][Full Text] [Related]
8. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
Bell R; Neiger R; McGrotty Y; Ramsey IK
Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
[TBL] [Abstract][Full Text] [Related]
9. Urinary corticoid: creatinine ratios in dogs with pituitary-dependent hypercortisolism during trilostane treatment.
Galac S; Buijtels JJ; Kooistra HS
J Vet Intern Med; 2009; 23(6):1214-9. PubMed ID: 19709356
[TBL] [Abstract][Full Text] [Related]
10. Clinical Relationship between Cholestatic Disease and Pituitary-Dependent Hyperadrenocorticism in Dogs: A Retrospective Case Series.
Kim KH; Han SM; Jeon KO; Kim HT; Li Q; Ryu MO; Song WJ; Park SC; Youn HY
J Vet Intern Med; 2017 Mar; 31(2):335-342. PubMed ID: 28064467
[TBL] [Abstract][Full Text] [Related]
11. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
Fracassi F; Corradini S; Floriano D; Boari A; Aste G; Pietra M; Bergamini PF; Dondi F
Vet Rec; 2015 Jan; 176(2):49. PubMed ID: 25170036
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
Braun C; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2013 Oct; 155(10):551-8. PubMed ID: 24091230
[TBL] [Abstract][Full Text] [Related]
14. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
15. Trilostane and the normal hypothalamic-pituitary-adrenocortical axis.
Semple CG; Thomson JA; Stark AN; McDonald M; Beastall GH
Clin Endocrinol (Oxf); 1982 Dec; 17(6):569-75. PubMed ID: 6299624
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
18. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.
Midence JN; Drobatz KJ; Hess RS
J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943
[TBL] [Abstract][Full Text] [Related]
19. Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial.
de Carvalho GLC; Meirelles L; da Silva CC; Neto WS; Furtado PV; Machado L; de Moura Martins FS; da Silva Mello FP; de Faria Valle S; Pöppl ÁG
Res Vet Sci; 2022 Dec; 150():107-114. PubMed ID: 35809414
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
